Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DAB + camptothecin
- Development stage
- Preclinical
- Modality
- Gene Therapies, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
DAB + camptothecin refers to an experimental nanoparticle-based co-delivery system designed for the treatment of prostate cancer. It utilizes a generation-3 diaminobutyric polypropylenimine (DAB) dendrimer that has been PEGylated to improve biocompatibility and loaded with the chemotherapeutic agent camptothecin. This complex is further combined with plasmid DNA to form "dendriplexes," facilitating a dual-modality approach that integrates chemotherapy with gene therapy. Camptothecin functions as a DNA topoisomerase I inhibitor, inducing apoptosis in cancer cells, while the DAB dendrimer serves as a cationic vector for the delivery and expression of therapeutic genes. Research into this system has explored the use of microfluidic processing to optimize its physicochemical properties, such as particle size and zeta potential, to enhance cellular uptake and transfection efficiency in prostate cancer cell lines like PC3 and DU145.
- Other names
- camptothecin-bearing PEGylated DAB dendriplexesPEGylated DAB-CPT dendriplexes
02
Targets
DNATOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on DAB + camptothecin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DAB + camptothecin.